|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Laskin JJ and Sandler AB: State of the art
in therapy for non-small cell lung cancer. Cancer Invest.
23:427–442. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Subramaniam S, Thakur RK, Yadav VK, Nanda
R, Chowdhury S and Agrawal A: Lung cancer biomarkers: State of the
art. J Carcinog. 12:32013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boffetta P and Nyberg F: Contribution of
environmental factors to cancer risk. Br Med Bull. 68:71–94. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ridge CA, McErlean AM and Ginsberg MS:
Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Wang Y and Wang J: MicroRNA-584
inhibits cell proliferation and invasion in non-small cell lung
cancer by directly targeting MTDH. Exp Ther Med. 15:2203–2211.
2018.PubMed/NCBI
|
|
7
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: New biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu G, Shao G, Pan Q, Sun L, Zheng D, Li M,
Li N, Shi H and Ni Y: MicroRNA-9 regulates non-small cell lung
cancer cell invasion and migration by targeting eukaryotic
translation initiation factor 5A2. Am J Transl Res. 9:478–488.
2017.PubMed/NCBI
|
|
9
|
National Lung Screening Trial Research
Team, . Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM,
Galen B, Gareen IF, Gatsonis C, Goldin J, et al: The National Lung
Screening Trial: Overview and study design. Radiology. 258:243–253.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Behm-Ansmant I, Rehwinkel J and Izaurralde
E: MicroRNAs silence gene expression by repressing protein
expression and/or by promoting mRNA decay. Cold Spring Harb Symp
Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Castro D, Moreira M, Gouveia AM, Pozza DH
and De Mello RA: MicroRNAs in lung cancer. Oncotarget.
8:81679–81685. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vannini I, Fanini F and Fabbri M: Emerging
roles of microRNAs in cancer. Curr Opin Genet Dev. 48:128–133.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramassone A, Pagotto S, Veronese A and
Visone R: Epigenetics and MicroRNAs in Cancer. Int J Mol Sci.
19(pii): E4592018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xia H, Li Y and Lv X: MicroRNA-107
inhibits tumor growth and metastasis by targeting the BDNF-mediated
PI3K/AKT pathway in human non-small lung cancer. Int J Oncol.
49:1325–1333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zang H, Peng J, Wang W and Fan S: Roles of
microRNAs in the resistance to platinum based chemotherapy in the
non-small cell lung cancer. J Cancer. 8:3856–3861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou Q, Huang SX, Zhang F, Li SJ, Liu C,
Xi YY, Wang L, Wang X, He QQ, Sun CC and Li DJ: MicroRNAs: A novel
potential biomarker for diagnosis and therapy in patients with
non-small cell lung cancer. Cell Prolif. 50:2017. View Article : Google Scholar
|
|
19
|
Florczuk M, Szpechcinski A and
Chorostowska-Wynimko J: miRNAs as biomarkers and therapeutic
targets in non-small cell lung cancer: Current perspectives. Target
Oncol. 12:179–200. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang N, Zhang Y and Liang H: microRNA-598
inhibits cell proliferation and invasion of glioblastoma by
directly targeting metastasis associated in colon cancer-1. Oncol
Res. Feb 14–2018.(Epub ahead of print). View Article : Google Scholar
|
|
21
|
Liu K, Sun X, Zhang Y, Liu L and Yuan Q:
MiR-598: A tumor suppressor with biomarker significance in
osteosarcoma. Life Sci. 188:141–148. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen J, Zhang H, Chen Y, Qiao G, Jiang W,
Ni P, Liu X and Ma L: miR-598 inhibits metastasis in colorectal
cancer by suppressing JAG1/Notch2 pathway stimulating EMT. Exp Cell
Res. 352:104–112. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cipollini M, Landi S and Gemignani F:
Bonafide targets of deregulated microRNAs in non-small cell lung
cancer as tool to identify novel therapeutic targets: A review.
Curr Pharm Des. 23:55–72. 2017.PubMed/NCBI
|
|
25
|
Gao Y, Zhang W, Han X, Li F, Wang X, Wang
R, Fang Z, Tong X, Yao S, Li F, et al: YAP inhibits squamous
transdifferentiation of Lkb1-deficient lung adenocarcinoma through
ZEB2-dependent DNp63 repression. Nat Commun. 5:46292014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hou Y, Zhen J, Xu X, Zhen K, Zhu B, Pan R
and Zhao C: miR-215 functions as a tumor suppressor and directly
targets ZEB2 in human non-small cell lung cancer. Oncol Lett.
10:1985–1992. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiao A, Sui M, Zhang L, Sun P, Geng D,
Zhang W, Wang X and Li J: MicroRNA-200c inhibits the metastasis of
non-small cell lung cancer cells by targeting ZEB2, an
epithelial-mesenchymal transition regulator. Mol Med Rep.
13:3349–3355. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cortinovis D, Monica V, Pietrantonio F,
Ceresoli GL, La Spina CM and Wannesson L: MicroRNAs in non-small
cell lung cancer: Current status and future therapeutic promises.
Curr Pharm Des. 20:3982–3990. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rolfo C, Fanale D, Hong DS, Tsimberidou
AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V,
Cicero G, et al: Impact of microRNAs in resistance to chemotherapy
and novel targeted agents in non-small cell lung cancer. Curr Pharm
Biotechnol. 15:475–485. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tibaldi C, D'Incecco A and Lagana A:
MicroRNAs and targeted therapies in non-small cell lung cancer:
Minireview. Anticancer Agents Med Chem. 15:694–700. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kurashige J, Kamohara H, Watanabe M,
Hiyoshi Y, Iwatsuki M, Tanaka Y, Kinoshita K, Saito S, Baba Y and
Baba H: MicroRNA-200b regulates cell proliferation, invasion, and
migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg
Oncol. 19 Suppl 3:S656–S664. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chu PY, Hu FW, Yu CC, Tsai LL, Yu CH, Wu
BC, Chen YW, Huang PI and Lo WL: Epithelial-mesenchymal transition
transcription factor ZEB1/ZEB2 co-expression predicts poor
prognosis and maintains tumor-initiating properties in head and
neck cancer. Oral Oncol. 49:34–41. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li MZ, Wang JJ, Yang SB, Li WF, Xiao LB,
He YL and Song XM: ZEB2 promotes tumor metastasis and correlates
with poor prognosis of human colorectal cancer. Am J Transl Res.
9:2838–2851. 2017.PubMed/NCBI
|
|
35
|
Sun DK, Wang JM, Zhang P and Wang YQ:
MicroRNA-138 regulates metastatic potential of bladder cancer
through ZEB2. Cell Physiol Biochem. 37:2366–2374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Q, Jiang H, Deng X, Fang W and Guo S:
Expressions of ZEB2 and C-myc in epithelial ovarian cancer and
their clinical significance. Nan Fang Yi Ke Da Xue Xue Bao.
35:1765–1769. 2015.(In Chinese). PubMed/NCBI
|
|
37
|
Prislei S, Martinelli E, Zannoni GF,
Petrillo M, Filippetti F, Mariani M, Mozzetti S, Raspaglio G,
Scambia G and Ferlini C: Role and prognostic significance of the
epithelial-mesenchymal transition factor ZEB2 in ovarian cancer.
Oncotarget. 6:18966–18979. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi ZM, Wang L, Shen H, Jiang CF, Ge X, Li
DM, Wen YY, Sun HR, Pan MH, Li W, et al: Downregulation of miR-218
contributes to epithelial-mesenchymal transition and tumor
metastasis in lung cancer by targeting Slug/ZEB2 signaling.
Oncogene. 36:2577–2588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fang S, Zeng X, Zhu W, Tang R, Chao Y and
Guo L: Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by
miR-200b contributes to multi-drug resistance of small cell lung
cancer. Exp Mol Pathol. 96:438–444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin X, Yang Z, Zhang P, Liu Y and Shao G:
miR-154 inhibits migration and invasion of human non-small cell
lung cancer by targeting ZEB2. Oncol Lett. 12:301–306. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hong-Yuan W and Xiao-Ping C: miR-338-3p
suppresses epithelial-mesenchymal transition and metastasis in
human nonsmall cell lung cancer. Indian J Cancer. 52 Suppl
3:E168–E171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang M, Zhong T, Zhang W, Xiao Z, Hu G,
Zhou H and Kuang H: Reduced expression of miR-205-5p promotes
apoptosis and inhibits proliferation and invasion in lung cancer
A549 cells by upregulation of ZEB2 and downregulation of erbB3. Mol
Med Rep. 15:3231–3238. 2017. View Article : Google Scholar : PubMed/NCBI
|
